Cintredekin besudotox clinical trials
Also written IL13-PE38QQR.
How each study uses cintredekin besudotox is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2001 (2)
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2001 | 2 |
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 2 |
| 2005 | 1 |
| 2009 | 1 |
| 2012 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 3
INSYS Therapeutics Inc (8) · Memorial Sloan Kettering Cancer Center (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1) · Pediatric Brain Tumor Consortium (1)
Often tested with
Tested in the same studies.
Carmustine, poliferprosan 20 drug combination (1)
Studies
Open first, then newest update. How each study uses cintredekin besudotox is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 11
- An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-grade GliomaTerminatedPhase 1National Institute of Neurological Disorders and Stroke (NINDS)NCT00880061Written as IL13-PE38QQRHow we know
- Possible New Therapy for Advanced CancerTerminatedPhase 1INSYS Therapeutics IncNCT01832974Written as IL-13-PEHow we know
- Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant GliomaCompletedPhase 1/2INSYS Therapeutics IncNCT00024570Written as IL13-PE38QQRHow we know
- Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant GliomaWithdrawnPhase 1/2INSYS Therapeutics IncNCT00378235Written as IL13-PE38QQRHow we know
- Immunotoxin Therapy Before and After Surgery in Treating Patients With Recurrent Malignant GliomaCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT00036972Written as cintredekin besudotoxHow we know
- IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant GliomaCompletedPhase 1INSYS Therapeutics IncNCT00089427Written as IL13-PE38QQRHow we know
- Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma PatientsCompletedPhase 1INSYS Therapeutics IncNCT00024557Written as IL13-PE38QQRHow we know
- The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma MultiformeCompletedPhase 3INSYS Therapeutics IncNCT00076986Written as IL13-PE38QQRHow we know
- Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant GliomaCompletedPhase 1INSYS Therapeutics IncNCT00064779Written as IL13-PE38QQRHow we know
- Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant GliomaCompletedPhase 1/2INSYS Therapeutics IncNCT00041587Written as IL13-PE38QQRHow we know
- Immunotoxin Therapy in Treating Children With Recurrent Malignant GliomasWithdrawnPhase 1/2Pediatric Brain Tumor ConsortiumNCT00053040Written as cintredekin besudotoxHow we know
Codes
What other systems call cintredekin besudotox · ClinicalTrials.gg INT005129
- UNII (FDA) ZL04JX89M7CINTREDEKIN BESUDOTOXConfirmed FDA, NLM
- NCI Thesaurus C2599Cintredekin BesudotoxOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | ZL04JX89M7 | CINTREDEKIN BESUDOTOX | Confirmed FDA, NLM |
| NCI Thesaurus | C2599 | Cintredekin Besudotox | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.